Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Pharmacol Res ; 167: 105548, 2021 05.
Article in English | MEDLINE | ID: mdl-33722710

ABSTRACT

Acute Respiratory Distress Syndrome (ARDS) is triggered by a variety of agents, including Staphylococcal Enterotoxin B (SEB). Interestingly, a significant proportion of patients with COVID-19, also develop ARDS. In the absence of effective treatments, ARDS results in almost 40% mortality. Previous studies from our laboratory demonstrated that resveratrol (RES), a stilbenoid, with potent anti-inflammatory properties can attenuate SEB-induced ARDS. In the current study, we investigated the role of RES-induced alterations in the gut and lung microbiota in the regulation of ARDS. Our studies revealed that SEB administration induced inflammatory cytokines, ARDS, and 100% mortality in C3H/HeJ mice. Additionally, SEB caused a significant increase in pathogenic Proteobacteria phylum and Propionibacterium acnes species in the lungs. In contrast, RES treatment attenuated SEB-mediated ARDS and mortality in mice, and significantly increased probiotic Actinobacteria phylum, Tenericutes phylum, and Lactobacillus reuteri species in both the colon and lungs. Colonic Microbiota Transplantation (CMT) from SEB-injected mice that were treated with RES as well as the transfer of L. reuteri into recipient mice inhibited the production of SEB-mediated induction of pro-inflammatory cytokines such as IFN-γ and IL-17 but increased that of anti-inflammatory IL-10. Additionally, such CMT and L. reuteri recipient mice exposed to SEB, showed a decrease in lung-infiltrating mononuclear cells, cytotoxic CD8+ T cells, NKT cells, Th1 cells, and Th17 cells, but an increase in the population of regulatory T cells (Tregs) and Th3 cells, and increase in the survival of mice from SEB-mediated ARDS. Together, the current study demonstrates that ARDS induced by SEB triggers dysbiosis in the lungs and gut and that attenuation of ARDS by RES may be mediated, at least in part, by alterations in microbiota in the lungs and the gut, especially through the induction of beneficial bacteria such as L. reuteri.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Colon/drug effects , Enterotoxins , Fecal Microbiota Transplantation , Gastrointestinal Microbiome/drug effects , Lung/drug effects , Respiratory Distress Syndrome/prevention & control , Resveratrol/pharmacology , Superantigens , Animals , Cell Line , Colon/immunology , Colon/metabolism , Colon/microbiology , Cytokines/metabolism , Disease Models, Animal , Dysbiosis , Female , Inflammation Mediators/metabolism , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/growth & development , Lung/immunology , Lung/metabolism , Lung/microbiology , Mice, Inbred C3H , Respiratory Distress Syndrome/immunology , Respiratory Distress Syndrome/metabolism , Respiratory Distress Syndrome/microbiology
2.
BJOG ; 127(2): 275-284, 2020 01.
Article in English | MEDLINE | ID: mdl-30932317

ABSTRACT

OBJECTIVE: To determine the effects on the vaginal microbiota of an oral probiotic preparation administered from early pregnancy. DESIGN: Randomised, double blind, placebo-controlled trial. SETTING: Four maternity units in the UK. POPULATION: Women aged 16 years or older recruited at 9-14 weeks' gestation. METHODS: Participants were randomly allocated to receive oral capsules of probiotic containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each at 2.5 × 109 colony-forming units (CFUs) or placebo once daily from recruitment until the end of pregnancy. MAIN OUTCOME MEASURE: Rates of bacterial vaginosis (BV, defined as Nugent score ≥7) at 18-20 weeks' gestation compared by logistic regression adjusted for possible confounders. RESULTS: The primary analysis included 78% (238/304) of participants who initially consented (probiotic group 123, placebo group 115). Of these participants, 95% (227/238) reported an intake of 93% or more of the required number of capsules. The rates of BV did not differ between groups at 18-20 weeks' gestation (15% (19/123) in the probiotic group vs. 9% (10/115) in the placebo group, adjusted odds ratio 1.82, 95% confidence interval 0.64-5.19). There were also no differences between the groups in the proportion of women colonised with the probiotic strains, Escherichia coli, group B streptococci or other vaginal microbiota. There were no differences in the alpha diversity or composition of the bacterial communities between or within the probiotic and placebo groups at 9-14 and 18-20 weeks' gestation. CONCLUSIONS: Oral probiotics taken from early pregnancy did not modify the vaginal microbiota. TWEETABLE ABSTRACT: The oral probiotic preparation used in this study does not prevent BV in pregnant women.


Subject(s)
Microbiota/physiology , Pregnancy Complications, Infectious/microbiology , Probiotics/therapeutic use , Vagina/microbiology , Adult , Double-Blind Method , Female , Humans , Limosilactobacillus reuteri/drug effects , Lacticaseibacillus rhamnosus/drug effects , Pregnancy , Pregnancy Trimester, First , Vaginosis, Bacterial/complications , Vaginosis, Bacterial/drug therapy , Vaginosis, Bacterial/microbiology , Young Adult
3.
Int J Mol Sci ; 21(24)2020 Dec 21.
Article in English | MEDLINE | ID: mdl-33371288

ABSTRACT

The ability to adhere to the intestinal mucus layer is an important property of probiotic bacteria. Lactobacillus reuteri strains ZJ615 and ZJ617 show low and high adhesion, respectively, to intestinal epithelial cells. In this study, we quantified bacterial cell wall-associated glyceraldehyde-3-phosphate dehydrogenases (cw-GAPDH) and bacterial cell membrane permeability in both strains using immunoblotting and flow cytometry, respectively. Highly adhesive L. reuteri ZJ617 possessed significantly more cw-GAPDH, higher cell membrane permeability, and significantly higher adhesive ability toward mucin compared with low-adhesive L. reuteri ZJ615. In vitro adhesion studies and analysis of interaction kinetics using the Octet, the system revealed significantly decreased interaction between L. reuteri and mucin when mucin was oxidized when bacterial surface proteins were removed when bacteria were heat-inactivated at 80 °C for 30 min, and when the interaction was blocked with an anti-GAPDH antibody. SWISS-MODEL analysis suggested intensive interactions between mucin glycans (GalNAcα1-O-Ser, GalNAcαSer, and Galß3GalNAc) and GAPDH. Furthermore, in vivo studies revealed significantly higher numbers of bacteria adhering to the jejunum, ileum, and colon of piglets orally inoculated with L. reuteri ZJ617 compared with those inoculated with L. reuteri ZJ615; this led to a significantly decreased rate of diarrhea in piglets inoculated with L. reuteri ZJ617. In conclusion, there are strong correlations among the abundance of cw-GAPDH in L. reuteri, the ability of the bacterium to adhere to the host, and the health benefits of this probiotic.


Subject(s)
Bacterial Adhesion , Epithelial Cells/drug effects , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Intestinal Mucosa/drug effects , Limosilactobacillus reuteri/physiology , Mucins/metabolism , Probiotics/pharmacology , Animals , Epithelial Cells/metabolism , Intestinal Mucosa/metabolism , Limosilactobacillus reuteri/drug effects , Swine
4.
J Cell Mol Med ; 22(3): 1972-1983, 2018 03.
Article in English | MEDLINE | ID: mdl-29316223

ABSTRACT

Streptococcus mutans contributes significantly to dental caries, which arises from homoeostasic imbalance between host and microbiota. We hypothesized that Lactobacillus sp. inhibits growth, biofilm formation and gene expression of Streptococcus mutans. Antibacterial (agar diffusion method) and antibiofilm (crystal violet assay) characteristics of probiotic Lactobacillus sp. against Streptococcus mutans (ATCC 25175) were evaluated. We investigated whether Lactobacillus casei (ATCC 393), Lactobacillus reuteri (ATCC 23272), Lactobacillus plantarum (ATCC 14917) or Lactobacillus salivarius (ATCC 11741) inhibit expression of Streptococcus mutans genes involved in biofilm formation, quorum sensing or stress survival using quantitative real-time polymerase chain reaction (qPCR). Growth changes (OD600) in the presence of pH-neutralized, catalase-treated or trypsin-treated Lactobacillus sp. supernatants were assessed to identify roles of organic acids, peroxides and bacteriocin. Susceptibility testing indicated antibacterial (pH-dependent) and antibiofilm activities of Lactobacillus sp. against Streptococcus mutans. Scanning electron microscopy revealed reduction in microcolony formation and exopolysaccharide structural changes. Of the oral normal flora, L. salivarius exhibited the highest antibiofilm and peroxide-dependent antimicrobial activities. All biofilm-forming cells treated with Lactobacillus sp. supernatants showed reduced expression of genes involved in exopolysaccharide production, acid tolerance and quorum sensing. Thus, Lactobacillus sp. can inhibit tooth decay by limiting growth and virulence properties of Streptococcus mutans.


Subject(s)
Antibiosis , Biofilms/drug effects , Ligilactobacillus salivarius/growth & development , Probiotics/pharmacology , Streptococcus mutans/drug effects , Bacteriocins/pharmacology , Biofilms/growth & development , Catalase/pharmacology , Culture Media/chemistry , Humans , Hydrogen-Ion Concentration , Interferon-gamma/biosynthesis , Interleukin-10/biosynthesis , Lacticaseibacillus casei/drug effects , Lacticaseibacillus casei/growth & development , Lacticaseibacillus casei/metabolism , Lactobacillus plantarum/drug effects , Lactobacillus plantarum/growth & development , Lactobacillus plantarum/metabolism , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/growth & development , Limosilactobacillus reuteri/metabolism , Ligilactobacillus salivarius/drug effects , Ligilactobacillus salivarius/metabolism , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/microbiology , Microbial Sensitivity Tests , Peroxides/pharmacology , Polysaccharides, Bacterial/antagonists & inhibitors , Polysaccharides, Bacterial/biosynthesis , Primary Cell Culture , Quorum Sensing/drug effects , Streptococcus mutans/genetics , Streptococcus mutans/growth & development , Streptococcus mutans/pathogenicity , Trypsin/pharmacology
5.
Appl Microbiol Biotechnol ; 101(11): 4495-4505, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28258313

ABSTRACT

Previously, we have shown that the glucansucrase GtfA-ΔN enzyme of Lactobacillus reuteri 121, incubated with sucrose, efficiently glucosylated catechol and we structurally characterized catechol glucosides with up to five glucosyl units attached (te Poele et al. in Bioconjug Chem 27:937-946, 2016). In the present study, we observed that upon prolonged incubation of GtfA-ΔN with 50 mM catechol and 1000 mM sucrose, all catechol had become completely glucosylated and then started to reappear. Following depletion of sucrose, this glucansucrase GtfA-ΔN used both α-D-Glcp-catechol and α-D-Glcp-(1→4)-α-D-Glcp-catechol as donor substrates and transferred a glucose unit to other catechol glycoside molecules or to sugar oligomers. In the absence of sucrose, GtfA-ΔN used α-D-Glcp-catechol both as donor and acceptor substrate to synthesize catechol glucosides with 2 to 10 glucose units attached and formed gluco-oligosaccharides up to a degree of polymerization of 4. Also two other glucansucrases tested, Gtf180-ΔN from L. reuteri 180 and GtfML1-ΔN from L. reuteri ML1, used α-D-Glcp-catechol and di-glucosyl-catechol as donor/acceptor substrate to synthesize both catechol glucosides and gluco-oligosaccharides. With sucrose as donor substrate, the three glucansucrase enzymes also efficiently glucosylated the phenolic compounds pyrogallol, resorcinol, and ethyl gallate; also these mono-glucosides were used as donor/acceptor substrates.


Subject(s)
Catechols/metabolism , Glucosides/metabolism , Glycosyltransferases/metabolism , Limosilactobacillus reuteri/enzymology , Bacterial Proteins/chemistry , Bacterial Proteins/metabolism , Catechols/pharmacology , Crystallography, X-Ray , Gallic Acid/analogs & derivatives , Gallic Acid/metabolism , Glucose/metabolism , Glycosylation , Glycosyltransferases/biosynthesis , Limosilactobacillus reuteri/drug effects , Oligosaccharides/chemistry , Pyrogallol/metabolism , Resorcinols/metabolism , Sucrose/pharmacology
6.
Biotechnol Lett ; 39(10): 1547-1551, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28623443

ABSTRACT

OBJECTIVE: To examine whether choline and its derivatives can be used to preserve viable cells of Lactobacillus reuteri in autolytic models. RESULTS: A phosphate-induced autolytic model in de Man, Rogosa and Sharpe medium (MRS) was used. Viable cell counts were determined by plated on MRS-agar. Choline and hemicholinium-3 (HC-3) significantly blocked autolysis of L. reuteri at 360 mM and 4 mM, respectively. Viable cell counts corroborated these observations. Importantly, autolytically induced cells treated with choline and hemicholinium-3 were significantly more viable then even non-induced cells. Over-production of a known autolytic protein, spirosin, was not attenuated in the presence of choline and hemicholinium-3. CONCLUSION: Inducing autolysis and then blocking it with choline and its analogs is a promising approach for retaining the viability of L. reuteri cells.


Subject(s)
Bacteriolysis/drug effects , Choline/pharmacology , Hemicholinium 3/pharmacology , Limosilactobacillus reuteri/physiology , Bacterial Proteins/metabolism , Gene Expression Regulation, Bacterial/drug effects , Limosilactobacillus reuteri/drug effects , Microbial Viability , Phosphates/adverse effects , Probiotics
7.
Int J Food Sci Nutr ; 67(2): 92-8, 2016.
Article in English | MEDLINE | ID: mdl-26804428

ABSTRACT

Eaten foodstuffs are usually fortified with prebiotic ingredients, such as inulin and oligofructose (FOS). The main goal of this study was to evaluate the combined effects of inulin and FOS with either suboptimal pH or storage temperature on the viability of Lactobacillus reuteri DSM 20016. Data were modeled through Weibull equation for the evaluation of the microbiological shelf life and the survival time. Prebiotics enhanced the microbiological shelf life and enhanced the survival time of the target bacterium. The use of the factorial ANOVA highlighted that inulin and FOS exerted a different effect as a function of pH and temperature. Inulin prolonged survival time under acidic conditions, while the effect of glucose + FOS was significant at pH 8. Finally, temperature could act by increasing or decreasing the effect of prebiotics, as they could exert a protective effect at 30 °C but not at 44 °C. As the main output of this research, we could suggest that the effect of prebiotics on L. reuteri could be significantly affected by pH and temperature, thus pinpointing that the design of a symbiotic food should also rely on these factors.


Subject(s)
Limosilactobacillus reuteri/physiology , Prebiotics , Temperature , Glucose/pharmacology , Hydrogen-Ion Concentration , Inulin/pharmacology , Kinetics , Limosilactobacillus reuteri/drug effects , Models, Biological , Oligosaccharides/pharmacology
8.
J Appl Microbiol ; 117(1): 227-38, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24712513

ABSTRACT

AIMS: To evaluate an alginate-chitosan microcapsule for an intestinal probiotic delivery system for broilers. METHODS AND RESULTS: Lactobacillus reuteri KUB-AC5 was successfully microencapsulated with alginate and chitosan mixtures using an emulsion cross-linking method with high microencapsulation efficiency. Scanning electron microscopy revealed a large number of the bacteria entrapped in the semi-interpenetrating network. The microcapsule effectively protected the cells against strong acids. The in vitro study showed that the 8 log CFU g(-1) was released at the jejunum and ileum. For the in vivo study, the number of probiotics was detected by a polymerase chain reaction-based random amplified polymorphic DNA technique. From provision of 10 log CFU, cell numbers of 5-8 log CFU were observed in the intestine. CONCLUSIONS: The alginate-chitosan microcapsule can serve as a potential intestine-targeted probiotic delivery system. SIGNIFICANCE AND IMPACTS OF THE STUDY: To the best of our knowledge, this is the first comparison study of the in vitro and in vivo gastrointestinal profiles of microencapsulated probiotics used as feed additives for broilers. This study reveals the similarities and differences of the in vitro and in vivo probiotic profiles and provides convincing evidence of the potential use of the alginate-chitosan microcapsule as a probiotic delivery system.


Subject(s)
Alginates/chemistry , Chickens/microbiology , Chitosan/chemistry , DNA, Bacterial/isolation & purification , Limosilactobacillus reuteri/physiology , Probiotics/pharmacology , Animals , Bile Acids and Salts/pharmacology , Capsules , Drug Carriers , Drug Compounding , Emulsions , Gastric Juice/chemistry , Glucuronic Acid/chemistry , Hexuronic Acids/chemistry , Hydrogen-Ion Concentration , Ileum/microbiology , Jejunum/microbiology , Limosilactobacillus reuteri/chemistry , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/ultrastructure , Microscopy, Electron, Scanning , Polymerization , Random Amplified Polymorphic DNA Technique
9.
Antonie Van Leeuwenhoek ; 105(3): 579-92, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24488273

ABSTRACT

The gut microbiome may modulate intestinal immunity by luminal conversion of dietary amino acids to biologically active signals. The model probiotic organism Lactobacillus reuteri ATCC PTA 6475 is indigenous to the human microbiome, and converts the amino acid L-histidine to the biogenic amine, histamine. Histamine suppresses tumor necrosis factor (TNF) production by human myeloid cells and is a product of L-histidine decarboxylation, which is a proton-facilitated reaction. A transposon mutagenesis strategy was developed based on a single-plasmid nisin-inducible Himar1 transposase/transposon delivery system for L. reuteri. A highly conserved proton-chloride antiporter gene (eriC), a gene widely present in the gut microbiome was discovered by Himar1 transposon (Tn)-mutagenesis presented in this study. Genetic inactivation of eriC by transposon insertion and genetic recombineering resulted in reduced ability of L. reuteri to inhibit TNF production by activated human myeloid cells, diminished histamine production by the bacteria and downregulated expression of histidine decarboxylase cluster genes compared to those of WT 6475. EriC belongs to a large family of ion transporters that includes chloride channels and proton-chloride antiporters and may facilitate the availability of protons for the decarboxylation reaction, resulting in histamine production by L. reuteri. This report leverages the tools of bacterial genetics for probiotic gene discovery. The findings highlight the widely conserved nature of ion transporters in bacteria and how ion transporters are coupled with amino acid decarboxylation and contribute to microbiome-mediated immunomodulation.


Subject(s)
Antiporters/genetics , Antiporters/metabolism , DNA Transposable Elements , Histamine/biosynthesis , Limosilactobacillus reuteri/genetics , Limosilactobacillus reuteri/metabolism , Mutagenesis , Biological Transport , Chlorides/metabolism , Gene Expression , Gene Expression Regulation, Bacterial , Gene Order , Gene Silencing , Genetic Vectors/genetics , Histidine Decarboxylase/genetics , Limosilactobacillus reuteri/drug effects , Multigene Family , Mutagenesis, Insertional , Probiotics , Promoter Regions, Genetic , Protons , Tumor Necrosis Factors/pharmacology
10.
Nucleic Acids Res ; 40(10): e76, 2012 May.
Article in English | MEDLINE | ID: mdl-22328729

ABSTRACT

The ability to efficiently generate targeted point mutations in the chromosome without the need for antibiotics, or other means of selection, is a powerful strategy for genome engineering. Although oligonucleotide-mediated recombineering (ssDNA recombineering) has been utilized in Escherichia coli for over a decade, the successful adaptation of ssDNA recombineering to gram-positive bacteria has not been reported. Here we describe the development and application of ssDNA recombineering in lactic acid bacteria. Mutations were incorporated in the chromosome of Lactobacillus reuteri and Lactococcus lactis without selection at frequencies ranging between 0.4% and 19%. Whole genome sequence analysis showed that ssDNA recombineering is specific and not hypermutagenic. To highlight the utility of ssDNA recombineering we reduced the intrinsic vancomymycin resistance of L. reuteri >100-fold. By creating a single amino acid change in the D-Ala-D-Ala ligase enzyme we reduced the minimum inhibitory concentration for vancomycin from >256 to 1.5 µg/ml, well below the clinically relevant minimum inhibitory concentration. Recombineering thus allows high efficiency mutagenesis in lactobacilli and lactococci, and may be used to further enhance beneficial properties and safety of strains used in medicine and industry. We expect that this work will serve as a blueprint for the adaptation of ssDNA recombineering to other gram-positive bacteria.


Subject(s)
Genetic Engineering/methods , Homologous Recombination , Lactococcus lactis/genetics , Limosilactobacillus reuteri/genetics , Anti-Bacterial Agents/pharmacology , DNA Mismatch Repair , DNA, Single-Stranded/metabolism , Genome, Bacterial , Lactobacillus/genetics , Limosilactobacillus reuteri/drug effects , Mutation , Phenotype , Vancomycin/pharmacology
11.
Lett Appl Microbiol ; 58(3): 278-84, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24251876

ABSTRACT

UNLABELLED: Use of stevia-derived sweeteners was recently officially approved by the European Commission, and their application in the food industry has increased, especially in functional foods. However, there are scarce data about the influence of stevia on probiotic bacteria, which are important both as an inhabitant of the human gut and as a functional food additive. Taking into consideration the broad application of Lactobacillus reuteri in functional foods, the aim of the research was to evaluate the influence of stevia glycosides on its growth. Six Lact. reuteri strains were tested for their ability to grow in the presence of stevioside and rebaudioside A (0·2-2·6 g l(-1) ). The effect of stevia glycosides on biomass concentration, cell count, pH and lactic and acetic acid synthesis was analysed. Both glycosides impaired the growth of analysed strains. However, the inhibitory effect was strain specific, and the concentration-dependent effect was not observed for all parameters. The most pronounced concentration-dependent effect was on lactic and acetic acid production. Taking into account the observed strain-specific inhibitory effect of stevia glycosides, it could be suggested to evaluate the influence of them on each strain employed before their simultaneous application in functional foods. SIGNIFICANCE AND IMPACT OF THE STUDY: The study showed that the growth of Lactobacillus reuteri strains was inhibited in the presence of stevia sweeteners stevioside and rebaudioside A. Probiotics, for example Lact. reuteri strains, are often used as functional additives in health foods and are an important natural inhabitant of the human gastrointestinal tract. Stevia glycosides application in food is increasing; yet, there are no data about the influence of stevia glycosides on Lact. reuteri growth and very few data on growth of other lactobacilli, either in probiotic foods or in the gastrointestinal tract. This research shows that it is necessary to evaluate the influence of stevia glycosides on other groups of micro-organisms in further research.


Subject(s)
Diterpenes, Kaurane/pharmacology , Glucosides/pharmacology , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/growth & development , Stevia/chemistry , Sweetening Agents/pharmacology , Diterpenes, Kaurane/adverse effects , Glucosides/adverse effects , Sweetening Agents/adverse effects
12.
Int J Food Sci Nutr ; 65(8): 977-80, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25088723

ABSTRACT

Traditional leafy vegetables, apart from being a staple in the diet of most of sub-Saharan Africa, are an essential part of traditional medicine and are used daily by traditional healers in the region to treat a wide variety of ailments. In this study, a batch culture technique was used to investigate whether 25 infusions from 22 traditional leafy vegetables stimulated the growth of Lactobacillus bulgaricus, Lactobacillus lactis, Lactobacillus reuteri and Bifidobacterium longum in pure culture. High performance liquid chromatography was used to determine the inulin content of the infusions. Sonchus oleraceus stimulated all four strains and Taraxacum officinale stimulated three strains. In total, 18 plants stimulated at least one of the four probiotic strains. The inulin content of the infusions varied between 2.5% and 3.6%, with Asparagus sprengeri containing the highest percentage. These results indicate that traditional leafy vegetables do stimulate the growth of the selected lactobacilli and bifidobacteria in pure culture and contain inulin. These infusions can now be tested for prebiotic potential using mixed culture systems or human hosts.


Subject(s)
Bifidobacterium/drug effects , Inulin/pharmacology , Lactobacillus/drug effects , Plant Extracts/pharmacology , Prebiotics , Probiotics , Vegetables/chemistry , Africa South of the Sahara , Asparagus Plant/chemistry , Bifidobacterium/growth & development , Diet , Humans , Lactobacillus/growth & development , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/growth & development , Medicine, African Traditional , Sonchus/chemistry , Taraxacum/chemistry
13.
Int J Food Microbiol ; 418: 110735, 2024 Jun 16.
Article in English | MEDLINE | ID: mdl-38761714

ABSTRACT

This research aimed to develop, optimize, and evaluate a new antifungal nanoemulsion system based on the crude reuterin-synergistic essential oils (EOs) hybrid to overcome the EOs application limits. At first, the antifungal effects of the Lactobacillus plantarum and Lactobacillus reuteri cell-free extracts (CFE) were tested against the Botrytis cinerea, Penicillium expansum, and Alternaria alternata as indicator fungus using broth microdilution method. The L. reuteri CFE with the MIC of 125 µL/mL for B. cinerea and 250 µL/mL for P. expansum and A. alternata showed more inhibitory effects than L. plantarum. Next, reuterin as a significant antibacterial compound in the L. reuteri CFE was induced in glycerol-containing culture media. To reach a nanoemulsion with maximum antifungal activity and stability, the reuterin concentration, Tween 80 %, and ultrasound time were optimized using response surface methodology (RSM) with a volumetric constant ratio of 5 % v/v oil phase including triple synergistic EOs (thyme, cinnamon, and rosemary) at MIC concentrations. Based on the Box-Behnken Design, the maximum antifungal effect was observed in the treatment with 40 mM reuterin, 1 % Tween 80, and 3 min of ultrasound. The growth inhibitory diameter zones of B. cinerea, P. expansum, and A. alternata were estimated 6.15, 4.25, and 4.35 cm in optimum nanoemulsion, respectively. Also, the minimum average particle size diameter (16.3 nm) was observed in nanoemulsion with reuterin 40 mM, Tween 80 5 %, and 3 min of ultrasound treatment. Zeta potential was relatively high within -30 mV range in all designed nanoemulsions which indicates the nanoemulsion's stability. Also, the prepared nanoemulsions, despite initial particle size showed good stability in a 90-d storage period at 25 °C. In vivo assay, showed a significant improvement in the protection of apple fruit treated with reuterin-EOs nanoemulsions against fungal spoilage compared to free reuterin nanoemulsion. Treatment of apples with nanoemulsion containing 40 mM reuterin showed a maximum inhibitory effect on B. cinerea (5.1 mm lesion diameter compared to 29.2 mm for control fruit) within 7 d at 25 °C. In summary, the present study demonstrated that reuterin-synergistic EOs hybrid with boosted antifungal activities can be considered as a biopreservative for food applications.


Subject(s)
Antifungal Agents , Emulsions , Glyceraldehyde , Oils, Volatile , Propane , Oils, Volatile/pharmacology , Oils, Volatile/chemistry , Emulsions/pharmacology , Propane/pharmacology , Propane/chemistry , Antifungal Agents/pharmacology , Antifungal Agents/chemistry , Glyceraldehyde/pharmacology , Glyceraldehyde/analogs & derivatives , Microbial Sensitivity Tests , Limosilactobacillus reuteri/drug effects , Penicillium/drug effects , Penicillium/growth & development , Botrytis/drug effects , Botrytis/growth & development , Alternaria/drug effects , Alternaria/growth & development
14.
Chem Pharm Bull (Tokyo) ; 61(6): 604-10, 2013.
Article in English | MEDLINE | ID: mdl-23727774

ABSTRACT

Three phenyl derivatives of butyrate, 2-phenylbutyrate (2-PB), 3-phenylbutyrate (3-PB) and 4-phenylbutyrate (4-PB), were evaluated in terms of their antibacterial and cytotoxic activities. Our results indicated that PBs demonstrated specific inhibitory activity against Helicobacter pylori and Escherichia coli but did not influence the growth of Bifidobacterium bifidium and Lactobacillus reuteri. PBs also exhibited synergistic effects on H. pylori ATCC 43504 especially at pH 5.5. In the protein expression profiles in H. pylori treated by phenylbutyrates, we also found that three protein spots identified as oxidative stress-related proteins were significantly up-regulated, confirming the response of H. pylori when exposed to PBs. Due to their antibacterial activities and low or slight cytotoxicities, PBs are potential candidates for the treatment of H. pylori infection. This is the first study to discover the antibiotic effects of 2-PB, 3-PB and 4-PB (Buphenyl).


Subject(s)
Anti-Infective Agents/pharmacology , Helicobacter pylori/drug effects , Phenylbutyrates/pharmacology , Animals , Anti-Infective Agents/chemistry , Anti-Infective Agents/toxicity , Bacterial Proteins/metabolism , Bifidobacterium/drug effects , Bifidobacterium/growth & development , Cell Line , Cell Survival/drug effects , Cricetinae , Drug Synergism , Escherichia coli/drug effects , Helicobacter pylori/metabolism , Hydrogen-Ion Concentration , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/growth & development , Metronidazole/pharmacology , Microbial Sensitivity Tests , Phenylbutyrates/chemistry , Phenylbutyrates/toxicity , Up-Regulation
15.
Can J Microbiol ; 58(6): 776-87, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22642667

ABSTRACT

Lactobacillus reuteri NCIMB 30253 was shown to have potential as a probiotic by reducing the proinflammatory chemokine interleukin-8. Moreover, this strain was evaluated, by in vitro and in vivo techniques, for its safety for human consumption. The identity of the strain was investigated by metabolic profiling and 16S rRNA gene sequencing, and in vitro safety evaluations were performed by molecular and metabolic techniques. Genetic analysis was confirmed by assessing the minimum inhibitory concentration to a panel of antibiotics, showing that the strain was susceptible to 8 antibiotics tested. The ability of the strain to produce potentially harmful by-products and antimicrobial compounds was evaluated, showing that the strain does not produce biogenic amines and does not show bacteriocin activity or reuterin production. A 28-day repeated oral dose study was conducted in normal Sprague-Dawley rats to support the in vivo strain safety. Oral administration of the strain resulted in no changes in general condition and no clinically significant changes to biochemical and haematological markers of safety relative to vehicle control treated animals. This comprehensive assessment of safety of L. reuteri NCIMB 30253 supports the safety of the strain for use as a probiotic.


Subject(s)
Limosilactobacillus reuteri/physiology , Probiotics/therapeutic use , Animals , Anti-Bacterial Agents/pharmacology , Glyceraldehyde/analogs & derivatives , Glyceraldehyde/metabolism , Humans , Interleukin-8/metabolism , Limosilactobacillus reuteri/drug effects , Male , Microbial Sensitivity Tests , Propane/metabolism , Rats , Rats, Sprague-Dawley
16.
J Appl Microbiol ; 111(2): 474-83, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21645181

ABSTRACT

AIM: The aims of this study were to identify antifungal lactic acid bacteria (LAB) and characterize their activity against the dermatophyte Trichophyton tonsurans. METHODS AND RESULTS: A total of 165 different LAB were isolated and initially screened for anti-Penicillium expansum activity. Five strains, which exhibited strong inhibitory activity, were then tested against the dermatophyte T. tonsurans DSM12285, where they also caused inhibition as observed by large fungal clearing on agar surface. The strongest inhibition was seen with Lactobacillus reuteri R2. When freeze-dried cell-free supernatant powder from this strain was incorporated in culture medium at concentrations >1%, growth of fungal colony was inhibited. Conidia germination was also inhibited under these conditions as determined by microscopy. The anti-T. tonsurans activity of Lact. reuteri R2 was not affected neither by heat treatment nor by proteolytic treatment using pronase E and proteinase K, indicating that the responsible agent(s) were nonproteinaceous in nature. CONCLUSIONS: Lactobacillus reuteri R2 was identified as having strong inhibitory activity against the dermatophyte T. tonsurans DSMZ12285. SIGNIFICANCE AND IMPACT OF THE STUDY: LAB are naturally associated with many foods and are well recognized for their biopreservative properties. The use of these and/or their products may well provide alternative safe approaches for the inhibition of dermatophytic fungi.


Subject(s)
Antibiosis , Limosilactobacillus reuteri/physiology , Trichophyton/growth & development , Animals , Bread/microbiology , Cattle , Cheese/microbiology , Culture Media , DNA, Bacterial/genetics , Edible Grain/microbiology , Food Microbiology , Freeze Drying , Hot Temperature , Humans , Hydrogen-Ion Concentration , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/genetics , Mice , Peptide Hydrolases/pharmacology , RNA, Ribosomal, 16S/genetics , Spores, Fungal/growth & development , Swine
17.
Appl Microbiol Biotechnol ; 92(3): 609-16, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21626024

ABSTRACT

Freeze-drying is commonly used to preserve probiotics, but it could cause cell damage and loss of viability. The cryoprotectants play an important role in the conservation of viability during freeze-drying. In this study, we investigated the survival rates of Lactobacillus reuteri CICC6226 in the presence of cryoprotectants such as sucrose, trehalose, and reconstituted skim milk (RSM). In addition, we determined the activities of hexokinase (HK), pyruvate kinase (PK), lactate dehydrogenase (LDH), and ATPases immediately following the freeze-drying. The results showed that the differences in HK and PK activities with and without the cryoprotectants during freeze-drying were not significant, but cell viability and activities of LDH and ATPase were significantly different (P<0.01) prior to and after freeze-drying. Meanwhile, the results showed that the maintenance of the membrane integrity and fluidity was improved in the presence of the 10% trehalose or 10% RSM than other treatments during freeze-drying. These results have provided direct biochemical and metabolic evidence of injured cell during freeze-drying. Freeze-drying damaged membrane structure and function of cell and inactivated enzymes (LDH and ATPases). The results imply that LDH and ATPases are key markers and could be used to evaluate the effect of cryoprotectants on viability and metabolic activities of L. reuteri CICC6226 during freeze-drying.


Subject(s)
Cryoprotective Agents/metabolism , Freeze Drying/methods , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/radiation effects , Microbial Viability/drug effects , Microbial Viability/radiation effects , Adenosine Triphosphatases/metabolism , Animals , Cell Membrane/physiology , Hexokinase/metabolism , L-Lactate Dehydrogenase/metabolism , Limosilactobacillus reuteri/enzymology , Limosilactobacillus reuteri/physiology , Membrane Fluidity/drug effects , Membrane Fluidity/radiation effects , Milk , Pyruvate Kinase/metabolism , Sucrose/metabolism , Trehalose/metabolism
18.
Biotechnol Lett ; 33(11): 2265-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21744273

ABSTRACT

PURPOSE OF WORK: To study whether an active bile acid (BA) efflux occurs in Lactobacillus reuteri CRL 1098 as well as the nature (ATP or proton motive force [PMF] mediated primary transport) of the BA extrusion mechanism. BAs are powerful detergents which disorganize the lipid bilayer structure of cellular membranes. Specific bile resistance mechanisms (bile efflux, bile salt hydrolysis, and intrinsic architecture and composition of cell membrane the most prevalent) have been described in intestinal bacteria. L. reuteri, showed a significant degree of resistance to the toxic action of BA and the presence of an active efflux ATP-dependent of conjugated (taurocholic [TCA]) and free (cholic [CA]) BA in the CRL 1098 strain is now reported. However, due the high pKa (5.5) of cholic acid (CA) compared with the conjugated species, a significant fraction (between 35 and 50% at pH 6.5 and 5.2, respectively) of free BA also diffused passively, even in the absence of ATP. To our knowledge, our results represent the first evidence of ATP as the energy source involved in the BA extrusion in L. reuteri.


Subject(s)
Adenosine Triphosphate/metabolism , Cholic Acid/metabolism , Limosilactobacillus reuteri/metabolism , Taurocholic Acid/metabolism , Biological Transport, Active , Cholic Acid/toxicity , Limosilactobacillus reuteri/drug effects , Taurocholic Acid/toxicity
19.
J Gastroenterol ; 56(5): 442-455, 2021 05.
Article in English | MEDLINE | ID: mdl-33782752

ABSTRACT

BACKGROUND: We previously showed that supernatants of Lactobacillus biofilms induced an anti-inflammatory response by affecting the secretion of macrophage-derived cytokines, which was abrogated upon immunodepletion of the stress protein GroEL. METHODS: We purified GroEL from L. reuteri and analysed its anti-inflammatory properties in vitro in human macrophages isolated from buffy coats, ex vivo in explants from human biopsies and in vivo in a mouse model of DSS induced intestinal inflammation. As a control, we used GroEL purified (LPS-free) from E. coli. RESULTS: We found that L. reuteri GroEL (but not E. coli GroEL) inhibited pro-inflammatory M1-like macrophages markers, and favored M2-like markers. Consequently, L. reuteri GroEL inhibited pro-inflammatory cytokines (TNFα, IL-1ß, IFNγ) while favouring an anti-inflammatory secretome. In colon tissues from human biopsies, L. reuteri GroEL was also able to decrease markers of inflammation and apoptosis (caspase 3) induced by LPS. In mice, we found that rectal administration of L. reuteri GroEL (but not E. coli GroEL) inhibited all signs of haemorrhagic colitis induced by DSS including intestinal mucosa degradation, rectal bleeding and weight loss. It also decreased intestinal production of inflammatory cytokines (such as IFNγ) while increasing anti-inflammatory IL-10 and IL-13. These effects were suppressed when animals were immunodepleted in macrophages. From a mechanistic point of view, the effect of L. reuteri GroEL seemed to involve TLR4, since it was lost in TRL4-/- mice, and the activation of a non-canonical TLR4 pathway. CONCLUSIONS: L. reuteri GroEL, by affecting macrophage inflammatory features, deserves to be explored as an alternative to probiotics.


Subject(s)
Chaperonin 60/pharmacology , Colon/drug effects , Inflammation/prevention & control , Lactobacillus/metabolism , Animals , Chaperonin 60/therapeutic use , Colon/physiopathology , Disease Models, Animal , Inflammation/drug therapy , Limosilactobacillus reuteri/drug effects , Limosilactobacillus reuteri/metabolism , Mice, Inbred BALB C , Statistics, Nonparametric
20.
Appl Environ Microbiol ; 76(21): 7306-9, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20833791

ABSTRACT

The intestinal flora of mammals contains lactic acid bacteria (LAB) that may provide positive health effects for the host. Such bacteria are referred to as probiotic bacteria. From a pig, we have isolated a Lactobacillus reuteri strain that produces an antimicrobial peptide (AMP). The peptide was purified and characterized, and it was unequivocally shown that the AMP was a well-defined degradation product obtained from the mucus adhesion-promoting protein (MapA); it was therefore termed AP48-MapA. This finding demonstrates how large proteins might inherit unexpected pleiotropic functions by conferring antimicrobial capacities on the producer. The MapA/AP48-MapA system is the first example where a large protein of an intestinal LAB is shown to give rise to such an AMP. It is also of particular interest that the protein that provides this AMP is associated with the binding of the bacterium producing it to the surface/lining of the gut. This finding gives us new perspective on how some probiotic bacteria may successfully compete in this environment and thereby contribute to a healthy microbiota.


Subject(s)
Anti-Infective Agents/metabolism , Antimicrobial Cationic Peptides/biosynthesis , Limosilactobacillus reuteri/drug effects , Amino Acid Sequence , Animals , Anti-Infective Agents/isolation & purification , Antimicrobial Cationic Peptides/isolation & purification , Antimicrobial Cationic Peptides/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/isolation & purification , Bacterial Proteins/metabolism , Limosilactobacillus reuteri/isolation & purification , Limosilactobacillus reuteri/metabolism , Metagenome , Molecular Sequence Data , Swine/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL